ABBV Billionaire Ken Fisher's Top 15 Moves

What happened: Billionaire Ken Fisher's portfolio reveals a significant interest in AbbVie Inc. (ABBV), with the fund trimming its stake in 2020 but recently buying shares again. AbbVie, a leading pharmaceutical company, has consistently raised its dividend annually for over a decade, navigating a major patent cliff. It's forecasted a significant earnings increase this year, and its growth rate has been accelerating. On March 17, AbbVie inked a deal with Alloy Therapeutics to develop a next-generation antibody platform. However, on April 8, Cantor Fitzgerald lowered its price target for AbbVie to $240 from $250, citing weak pharma catalysts ahead.

Market impact: The pharmaceutical sector is affected, with AbbVie's strong dividend history and growth prospects drawing investor attention. The recent Cantor Fitzgerald price target reduction may cause some investors to reassess their positions. AbbVie's deal with Alloy Therapeutics could drive innovation and growth in the biotechnology sector.

What to watch next: AbbVie's Q1 earnings report, scheduled for April 29, will provide insights into the company's current performance and guidance. The market will also closely watch the progress of AbbVie's new antibody platform development with Alloy Therapeutics. Additionally, investors should monitor any updates on AbbVie's patent portfolio and pipeline to assess the company's long-term growth prospects.